Early choline levels from 3-Tesla MR spectroscopy after exclusive radiation therapy in patients with clinically localized prostate cancer are predictive of plasmatic levels of PSA at 1 year

International Journal of Radiation Oncology Biology Physics

Volumn 81, Issue 4, 2011, Pages

  Crehange, Gilles ^a   Maingon, Philippe ^a   Gauthier, Melanie ^b   Parfait, Sebastien ^c   Cochet, Alexandre ^d   Mirjolet, Celine ^a   Bonnetain, Franck ^b   Cormier, Luc ^d   Brunotte, Francois ^c,d   Walker, Paul ^c,d  

^a CENTRE GEORGES FRANÇOIS LECLERC   (France)

^b EA 4184   (France)

^c UNIVERSITÉ DE BOURGOGNE   (France)

^d DIJON UNIVERSITY HOSPITAL   (France)

Author keywords

3 Tesla; Magnetic resonance spectroscopy; Prostate cancer; Radiation; Response monitoring

Indexed keywords

3 TESLA; BIOCHEMICAL CONTROL; CLINICAL OUTCOME; HORMONAL THERAPY; INTENSITY MODULATED RADIATION THERAPY; LOCALIZED PROSTATE CANCER; MR SPECTROSCOPY; PROSTATE CANCERS; PROSTATE SPECIFIC ANTIGEN; RADIATION RESPONSE; RESPONSE MONITORING; TIME-COURSE RESPONSE;

DISEASES; IRRADIATION; MAGNETIC RESONANCE; MAGNETIC RESONANCE SPECTROSCOPY; RADIATION;

RADIOTHERAPY;

CHOLINE; CITRIC ACID; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN; WATER;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; FOLLOW UP; HUMAN; INTENSITY MODULATED RADIATION THERAPY; IRRADIATION; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; TRANSURETHRAL RESECTION; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; ANDROGEN ANTAGONISTS; BODY WATER; CHEMOTHERAPY, ADJUVANT; CHOLINE; CITRIC ACID; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; ORGAN SIZE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY, INTENSITY-MODULATED; TIME FACTORS; TUMOR BURDEN;

EID: 80054102933     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2011.03.008     Document Type: Article

References (27)

1. S.J. Freedland, M.E. Sutter, and F. Dorey Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy: Prostate-specific antigen Urology 61 2003 365 369 (Pubitemid 36206534)
2. J.G. Trapasso, J.B. deKernion, and R.B. Smith The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy J Urol 152 1994 1821 1825 (Pubitemid 24322638)
3. L.L. Kestin, F.A. Vicini, and E.L. Ziaja Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy Cancer 86 1999 1557 1566 (Pubitemid 29489791)
4. M.J. Zelefsky, W. Shi, and Y. Yamada Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality Int J Radiat Oncol Biol Phys 75 2009 1350 1356
5. T.W. Scheenen, S.W. Heijmink, and S.A. Roell Three-dimensional proton MR spectroscopy of human prostate at 3 T without endorectal coil: Feasibility Radiology 245 2007 507 516 (Pubitemid 47612533)
6. A.A. Schricker, J.M. Pauly, and J. Kurhanewicz Dualband spectral-spatial RF pulses for prostate MR spectroscopic imaging Magn Reson Med 46 2001 1079 1087 (Pubitemid 33104295)
7. T.K. Tran, D.B. Vigneron, and N. Sailasuta Very selective suppression pulses for clinical MRSI studies of brain and prostate cancer Magn Reson Med 43 2000 23 33 (Pubitemid 30027109)
8. Crehange G, Parfait S, Liegard M, et al. Tumor volume and metabolism of prostate cancer determined by proton magnetic resonance spectroscopic imaging at 3T without endorectal coil reveal potential clinical implications in the context of radiation oncology. Int J Radiat Oncol Biol Phys. In press.
9. M.E. Ray, L.B. Levy, and E.M. Horwitz Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure Urology 68 2006 1257 1262 (Pubitemid 44880342)
10. P. Alcantara, A. Hanlon, and M.K. Buyyounouski Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death Cancer 109 2007 41 47 (Pubitemid 46120193)
11. F.A. Critz, A.K. Levinson, and W.H. Williams Prostate specific antigen nadir achieved by men apparently cured of prostate cancer by radiotherapy J Urol 161 1999 1199 1203 discussion 1203-1195
12. A.L. Hanlon, H. Diratzouian, and G.E. Hanks Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer Int J Radiat Oncol Biol Phys 53 2002 297 303 (Pubitemid 34522096)
13. D.S. Lamb, J.W. Denham, and D. Joseph A comparison of the prognostic value of early PSA test-based variables following external beam radiotherapy, with or without preceding androgen deprivation: Analysis of data from the TROG 96.01 randomized trial Int J Radiat Oncol Biol Phys 79 2011 385 391
14. W.R. Lee, A.L. Hanlon, and G.E. Hanks Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: The relationship between nadir level and disease-free survival J Urol 156 1996 450 453 (Pubitemid 126445360)
15. R. de Crevoisier, K. Slimane, and T. Messai Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy Ann Oncol 21 2010 808 814
16. J.W. Denham, D.S. Lamb, and D. Joseph PSA response signatures: A powerful new prognostic indicator after radiation for prostate cancer? Radiother Oncol 90 2009 382 388
17. J. Crook, C. Gillan, and I. Yeung PSA kinetics and PSA bounce following permanent seed prostate brachytherapy Int J Radiat Oncol Biol Phys 69 2007 426 433 (Pubitemid 47380099)
18. A.L. Hanlon, W.H. Pinover, and E.M. Horwitz Patterns and fate of PSA bouncing following 3D-CRT Int J Radiat Oncol Biol Phys 50 2001 845 849 (Pubitemid 32594825)
19. E.M. Horwitz, L.B. Levy, and H.D. Thames Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: A multiinstitutional pooled analysis Cancer 107 2006 1496 1502 (Pubitemid 44546909)
20. R.G. Stock, N.N. Stone, and J.A. Cesaretti Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: Descriptions and implications Int J Radiat Oncol Biol Phys 56 2003 448 453 (Pubitemid 36542902)
21. A. Toledano, L. Chauveinc, and T. Flam PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure: A study of 295 patients with a minimum 3-year followup Brachytherapy 5 2006 122 126
22. F.V. Coakley, H. Hricak, and A.E. Wefer Brachytherapy for prostate cancer: Endorectal MR imaging of local treatment-related changes Radiology 219 2001 817 821 (Pubitemid 32476279)
23. F.V. Coakley, H.S. Teh, and A. Qayyum Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: Preliminary experience Radiology 233 2004 441 448 (Pubitemid 39423803)
24. T. Joseph, D.A. McKenna, and A.C. Westphalen Pretreatment endorectal magnetic resonance imaging and magnetic resonance spectroscopic imaging features of prostate cancer as predictors of response to external beam radiotherapy Int J Radiat Oncol Biol Phys 73 2009 665 671
25. B. Pickett, J. Kurhanewicz, and F. Coakley Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 60 2004 1047 1055 (Pubitemid 39440788)
26. B. Pickett, J. Kurhanewicz, and J. Pouliot Three-dimensional conformal external beam radiotherapy compared with permanent prostate implantation in low-risk prostate cancer based on endorectal magnetic resonance spectroscopy imaging and prostate-specific antigen level Int J Radiat Oncol Biol Phys 65 2006 65 72
27. A. Kirilova, A. Damyanovich, and J. Crook 3D MR-spectroscopic imaging assessment of metabolic activity in the prostate during the PSA "bounce" following (125)Iodine brachytherapy Int J Radiat Oncol Biol Phys 79 2011 371 378